imipramine has been researched along with Hypopigmentation in 1 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Hypopigmentation: A condition caused by a deficiency or a loss of melanin pigmentation in the epidermis, also known as hypomelanosis. Hypopigmentation can be localized or generalized, and may result from genetic defects, trauma, inflammation, or infections.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orringer, JS | 1 |
| Lowe, L | 1 |
| Cha, KB | 1 |
1 other study available for imipramine and Hypopigmentation
| Article | Year |
|---|---|
Treatment of imipramine-induced dyspigmentation with Q-switched alexandrite laser therapy.
Topics: Aged; Antidepressive Agents, Tricyclic; Female; Humans; Hypopigmentation; Imipramine; Lasers, Solid- | 2010 |